This inventor holds 1 USPTO granted patent and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Orion Corporation. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Esa Kumpulainen: Innovator in Pharmaceutical Chemistry
Introduction
Esa Kumpulainen is a notable inventor based in Helsinki, Finland. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target the central nervous system.
Latest Patents
Kumpulainen holds a patent for a compound titled "2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2C antagonists." This patent describes compounds of formula I, wherein A is an optionally substituted five-membered unsaturated heterocyclic ring containing 1, 2, or 3 N, O, or S ring heteroatom(s). These compounds exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases or conditions of the peripheral or central nervous system. He has 1 patent to his name.
Career Highlights
Esa Kumpulainen is associated with Orion Corporation, a leading pharmaceutical company in Finland. His work focuses on innovative solutions for medical treatments, contributing to advancements in drug development.
Collaborations
Kumpulainen has collaborated with several professionals in his field, including Shouming Wang and Jarmo J Pystynen. These collaborations have enhanced the research and development efforts within his projects.
Conclusion
Esa Kumpulainen is a prominent figure in pharmaceutical innovation, with a focus on compounds that can significantly impact the treatment of neurological conditions. His contributions continue to shape the future of medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile